t o turn this into a whole new class of medicines: that requires something special. live biotherapeutics – disruptive new medicines live biotherapeutics are a regulated, emerging and disruptive new class of medicines, which have the potential to transform the way in which we treat many diseases. our live biotherapeutics are strains of gut commensal bacteria which have been originally isolated from healthy humans. understanding which of these genes – and their products – interact with the human body in a beneficial way is key to identifying new live biotherapeutics. 4d pharma at a glance leaders in an emerging field we are well positioned to turn world-class microbiome science into safer new therapies for patients. 4d has grown from pioneering microbiome research to the only integrated, world-leading live biotherapeutics company. watch our new video: 4dpharmaplc.com highly attractive safety profile toxicity and unwanted side effects are a constant challenge in drug development. our live biotherapeutics are originally isolated from healthy human donors and consequently have excellent safety profiles. 4d pharma plc annual report and accounts 2017 02 strategic report an integrated biopharma company microrx – our proprietary discovery platform our discovery platform, microrx, allows us to rapidly identify strains of gut bacteria which may have a therapeutic effect in specific diseases. using microrx, we interrogate our proprietary library of more than 6,000 bacterial strains for pathway-specific effects on the host immune system. functional screen microbiology immunology gut physiology mechanism of action microbiology immunology gut physiology development rcb scale-up lyophilisation stability safety potency source gut microbiota from healthy humans isolation individual bacterial strains on selective media identification of bacteria using genome sequencing mechanisms pre-clinical models efficacy pre-clinical models gastro-intestinal blautix irritable bowel syndrome rosburix ulcerative colitis thetanix crohn’s disease cns neurodegeneration autism others respiratory mrx0004 asthma mrx0001 allergic asthma immuno-oncology mrx518 solid tumours autoimmune mrx0006 rheumatoid arthritis mrx0002 multiple sclerosis others discovery pre-clinical development phase i phase ii phase iii development pipeline 03 4d pharma plc annual report and accounts 2017 4dpharmaplc.com s chairman’s statement with its upcoming programme of trials, 4d is well placed to deliver meaningful clinical data to support the use of live biotherapeutics across multiple indications increasing intellectual property estate helps secure our leading position in the field. i believe that through our upcoming programme of clinical trials, we are well positioned to achieve this. consequently, we are looking to address the ibs subtypes (ibs-c (constipation) and ibs-d (diarrhoea)) in our upcoming phase ii trial. the early stage of intervention in this trial further demonstrates the lower risk our live biotherapeutics represent in terms of safety, but also provides potential insights into how mrx0518 may influence treatment regimes post-surgery. performance 4d exploits the enhanced safety profiles of therapeutics that originate from a healthy human. intellectual property rights description in this rapidly developing field, 4d believes it is vital to actively pursue patent protection for the innovations made. focus areas having successfully established this leading position, 4d is commencing an extended programme of publications and conferences. we currently have 17 wholly owned live biotherapeutic programmes in the pipeline across various stages of development. these systems can be summarised as follows: 11 4d pharma plc annual report and accounts 2017 4dpharmaplc.com s why is it important? even if products are approved, they may still face subsequent regulatory difficulties which could result in delays and therefore financial loss. change in level of risk increase uk referendum to leave the european union (“eu”) – brexit the strategic report on pages 2 to 13 was approved by the board on 20 april 2018 and signed on its behalf by: duncan peyton chief executive officer 20 april 2018 13 4d pharma plc annual report and accounts 2017 4dpharmaplc.com s audit and risk committee a remuneration committee r chairman board of directors we believe in the importance of good corporate governance david norwood non-executive chairman a r david has had a long career building a number of science, technology and investment companies. duncan started his career in a bio-science start-up business, which ultimately went on to list on the london stock exchange, subsequently qualified as a corporate finance lawyer with addleshaw goddard, then addleshaw booth & co, and later joined 3i plc as an investment manager. prior to joining aquarius equity, alex worked for ip group plc, where he specialised in life sciences investments identifying, developing and advising a number of companies in its portfolio, some of which went on to list on aim. thomas has supported private equity and other investors in over 50 potential deal transactions, on targets in europe and the usa, from cash constrained/chapter 11 to cash rich with enterprise value of up to $1 billion. thomas has also acted as non-executive chairman at akcros holdings limited, penlan healthcare and quantum pharmaceutical. david norwood non-executive chairman 20 april 2018 15 4d pharma plc annual report and accounts 2017 4dpharmaplc.com g decision making continued the board meets both at regular intervals and also at short notice to consider specific matters (for example proposed material transactions). rsm uk audit llp was appointed as auditor in 2014 following a comprehensive tender process. all such awards vest after three years and are subject to individual performance criteria. these matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. we agreed with the audit committee that we would report to them all unadjusted differences in excess of £10,000 as well as differences below those thresholds that, in our view, warranted reporting on qualitative grounds. in addition, all internal activities related to research and development of new products are continuously monitored by the directors. in assessing control, the group takes into consideration potential voting rights that are currently exercisable. (c) segmental reporting an operating segment is a component of an entity that engages in business activities from which it may earn revenues and incur expenses, whose operating results are regularly reviewed by the group’s chief operating decision maker, being the chief executive officer, to make decisions about resources to be allocated to the segment and assess its performance, and for which discrete financial information is available. (h) intangible assets intellectual property and patents the carrying value of intangible fixed assets is reviewed annually for impairment whenever events or changes in circumstances indicate the carrying value may not be recoverable. the carrying value of software is reviewed for impairment if events or changes in circumstances indicate that the carrying value may not be recoverable, and is written down immediately to their recoverable amount. internally generated intangible assets expenditure on research activities is recognised in the statement of comprehensive income as incurred. cost based on latest contractual prices includes all costs incurred in bringing each product to its present location and condition. notes to the financial statements continued for the year ended 31 december 2017 4d pharma plc annual report and accounts 2017 40 financial statements 3. significant accounting policies continued (p) share capital proceeds on issue of shares are included in shareholders’ equity, net of transaction costs. ifrs 16 distinguishes leases and service contracts on the basis of whether an identifiable asset is controlled by a customer. furthermore, the classification of cash flows will also be affected as operating lease payments under ias 17 are presented as operating cash flows, whereas under the ifrs 16 model, the lease payments will be split into a principal and interest portion which will be presented as financing and operating cash flows respectively. notes to the financial statements continued for the year ended 31 december 2017 4d pharma plc annual report and accounts 2017 42 financial statements 6. staff costs year to 31 december 2017 year to 31 december 2016 research and research and development administrative total development administrative total £000 £000 £000 £000 £000 £000 wages and salaries 2,597 868 3,465 1,371 621 1,992 social security costs 528 104 632 201 74 275 pension contributions 51 26 77 32 14 46 share-based compensation 159 143 302 — 131 131 3,335 1,141 4,476 1,604 840 2,444 directors’ remuneration (including benefits in kind) included in the aggregate remuneration above comprised: emoluments for qualifying services — 252 252 — 252 252 directors’ emoluments (excluding social security costs, but including benefits in kind) disclosed above include £101,323 (31 december 2016: £101,238) paid to the highest paid director. 2,693 at 31 december 2017 33,159 on 3 october 2017 the company converted €6.052 million of existing loans into ordinary shares in 4d pharma leon, s.l.u. details of the share-based payments issued to employees in subsidiaries are included in note 21. notes to the financial statements continued for the year ended 31 december 2017 4d pharma plc annual report and accounts 2017 50 financial statements 12. investment and loans to subsidiaries continued subsidiary undertakings holding at 31 december subsidiary undertaking country of incorporation registered office principal activity 2017 4d pharma research limited scotland life sciences innovation building, cornhill road, aberdeen ab25 2zs research and development 100% 4d pharma cork limited ireland room 447, food sciences building, university college cork, western road, cork t12 yn60 research and development 100% 4d pharma leon, s.l.u. retained earnings retained earnings includes the accumulated profits and losses arising from the group statement of comprehensive income and certain items from other comprehensive income attributable to equity shareholders net of distributions to shareholders. the group may use forward exchange contracts as an economic hedge against currency risk, where cash flow can be judged with reasonable certainty. biomar microbial technologies, an entity in which antonio fernandez is a director, charged rent and building service costs to the group of £302,487 (31 december 2016: £104,987). all related party transactions during the current and previous year were considered to be at arm’s length. 4d pharma plc annual report and accounts 2017 4dpharmaplc.com f 61 auditor rsm uk audit llp 3 hardman street manchester m3 3hf nominated advisor and joint broker zeus capital limited 82 king street manchester m2 4wq and 10 old burlington street london w1s 3ag country of incorporation united kingdom company number 08840579 directors dr norwood (non-executive chairman) dj peyton aj stevenson t engelen (non-executive) company secretary and registered office ls dale 4d pharma plc 9 bond court leeds ls1 2jz joint broker bryan garnier & co. limited beaufort house 15 st. botolph street london ec3a 7bb registrar link asset services the registry 34 beckenham road beckenham kent br3 4tu company information 4d pharma plc annual report and accounts 2017 4d pharma plc 9 bond court leeds ls1 2jz